The verdict
Our read at a glance.
Whether adding thyroid hormone to a euthyroid person produces useful fat loss rather than expensive muscle loss.
- The signal
- The approved uses are well established: hypothyroidism, myxoedema and specific thyroid indications, with labelled products and continuing registered trials in thyroid disease and in settings such as cardiac and critical care. In people who are already euthyroid the picture is different and has been understood for a long time. Thyroid hormone raises energy expenditure, but it raises protein turnover as well, and the weight lost under supraphysiologic thyroid hormone includes a substantial lean component. FDA labelling for thyroid hormones addresses obesity use directly, and does so as a warning rather than an indication.
- The unknown
- How completely the hypothalamic-pituitary-thyroid axis recovers after repeated suppression cycles, which is the outcome that most affects users years later and is not systematically tracked.
- Our read
- The boxed warning was written about exactly this practice, and it is unusually direct for FDA labelling. Thyroid hormone in a euthyroid person is not a fat-loss drug with side effects; it is a drug that removes tissue indiscriminately and suppresses the gland you were relying on.
The mechanism
How it works.
Triiodothyronine is the active thyroid hormone. It enters cells, binds nuclear thyroid hormone receptors and changes transcription across most tissues, raising basal metabolic rate, mitochondrial density and the activity of the sodium-potassium pump, which is itself a significant consumer of energy. That is why energy expenditure rises. The same signalling raises protein turnover, and in a person who is not hypothyroid and is already in an energy deficit, that increased turnover pulls disproportionately on skeletal muscle. Meanwhile the pituitary senses the extra hormone and stops releasing TSH, so the thyroid gland reduces its own output. That is why stopping abruptly leaves the user hypothyroid for a period, and why the fatigue and rebound weight gain after a cycle are pharmacologically predictable rather than a failure of willpower.
Safety & regulatory boundary
The consequential part.
Approved for hypothyroidism and related thyroid conditions, not for weight loss. Thyroid hormone labelling in the United States carries an explicit boxed warning that these drugs should not be used for the treatment of obesity or weight loss, that in euthyroid patients doses within the range of normal requirements are ineffective for weight reduction, and that larger doses may produce serious or life-threatening toxicity, particularly when combined with sympathomimetic amines. Exogenous T3 suppresses TSH and endogenous production. Excess causes atrial fibrillation, bone loss and cardiac strain.
What's next
What we're watching.
Nothing new is expected pharmacologically. The relevant surveillance is on combination use with stimulants, which is the specific pattern the boxed warning names.
Context
Why this is discussed.
It reliably increases metabolic rate, it is cheap, it is a real prescription drug, and it is a fixture of contest preparation.
The evidence base
23 cited references.
Regulatory & labels3
Dr. Reddy's Labratories Inc. (FDA label) · 2024
SIGMAPHARM LABORATORIES, LLC (FDA label) · 2025
Genus Lifesciences (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · NA · RECRUITING · 2017-06-12
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-06-26
ClinicalTrials.gov · NA · COMPLETED · 2022-07-01
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · PHASE1 · COMPLETED · 2023-03-02
ClinicalTrials.gov · NA · COMPLETED · 2023-09-15
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2024-11-29
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-10
Indexed literature (PubMed)12
Calissendorff J · Lakartidningen · 2019
Idrees T et al. · Thyroid · 2020
Reinehr T · Mol Cell Endocrinol · 2010
Chang SC et al. · Chin J Physiol · 2022
Aeberli I et al. · J Clin Endocrinol Metab · 2010
Pelletier C et al. · Obes Rev · 2003
Krotkiewski M · Int J Obes Relat Metab Disord · 2000
Fischman A et al. · Medwave · 2018
Sánchez-Tusie A et al. · J Endocrinol · 2020
Clyde PW et al. · JAMA · 2003
Matsubayashi S et al. · Horm Metab Res · 1988
Lu MH et al. · Endocr Res · 1996
Keep reading